Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in StockDefense World · 5 days ago
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewsWire · Oct 14, 2026
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP CredentialsSeeking Alpha · Oct 12, 2026
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsGlobeNewsWire · Oct 7, 2026
Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider SellingDefense World · Oct 2, 2026
Medicare Lab Fee Changes Impact BillionToOne, CareDx DifferentlyBenzinga · Sep 23, 2026BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | $0.18 | $0.15 | Miss |
| May 6, 2026 | $0.01 | $0.34 | Beat |
| Mar 4, 2026 | $0.07 | $0.11 | Beat |
| Dec 9, 2025 | $0.14 | $0.10 | Miss |
| Oct 7, 2025 | $0.14 | -$0.02 | Miss |